Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Makena SQ vs IM Injection Pain in Healthy Post-menopausal Women
NCT02937766Phase 3Terminated
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Oct 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxyprogesterone caproate in preterm birth (2 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoint: Comparison of Average Pain Intensity at 4 weeks. Started Oct 2016; status: terminated.
02
Drugs
hydroxyprogesterone caproate
03
Conditions
preterm birth
Beyond the preview
Go deeper on NCT02937766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937766.